Early changes in prefrontal activity characterize clinical responders to antidepressants

被引:158
作者
Cook, IA
Leuchter, AF
Morgan, M
Witte, E
Stubbeman, WF
Abrams, M
Rosenberg, S
Uijtdehaage, SHJ
机构
[1] Univ Calif Los Angeles, Neuropsychiat Inst & Hosp, Quantitat EEC Lab, Los Angeles, CA 90024 USA
[2] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Sch Med, Los Angeles, CA 90024 USA
关键词
depression; antidepressant response; prefrontal; EEG; cordance; response prediction;
D O I
10.1016/S0893-133X(02)00294-4
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Previous studies have shown that changes in brain function precede clinical response to antidepressant medications. Here we examined quantitative EEG (QEEG) absolute and relative power and a new measure, cordance, for detecting regional changes associated with treatment response. Fifty-one adults with unipolar depression completed treatment trials using either fluoxetine or venlafaxine vs. placebo. Data were recorded at baseline and after 48 h and 1 week on drug or placebo. Baseline and change from baseline values were examined for specific brain regions in four subject groups (medication and placebo responders and nonresponders). No regional baseline QEEG differences were found among the groups; there also were no significant changes in theta power over time. In contrast, medication responders uniquely showed significant decreases in prefrontal cordance at 48 h and I week, Clinical differences did not emerge until after four weeks. Subjects with greater changes in cordance had the most complete 8-week responses, These findings implicate the prefrontal region in mediating response to antidepressant medications. Cordance may have clinical applicability as a leading indicator of individual response. (C) 2002 American College of Neuropsychopharmacology. Published by Elsevier Science Inc.
引用
收藏
页码:120 / 131
页数:12
相关论文
共 58 条
  • [1] Plasma serotonin level after 1 day of fluoxetine treatment:: a biological predictor for antidepressant response?
    Alvarez, JC
    Gluck, N
    Fallet, A
    Grégoire, A
    Chevalier, JF
    Advenier, C
    Spreux-Varoquaux, O
    [J]. PSYCHOPHARMACOLOGY, 1999, 143 (01) : 97 - 101
  • [2] SINGLE PHOTON-EMISSION TOMOGRAPHY WITH TC-99M-EXAMETAZIME IN MAJOR DEPRESSION AND THE PATTERN OF BRAIN ACTIVITY UNDERLYING THE PSYCHOTIC NEUROTIC CONTINUUM
    AUSTIN, MP
    DOUGALL, N
    ROSS, M
    MURRAY, C
    OCARROLL, RE
    MOFFOOT, A
    EBMEIER, KP
    GOODWIN, GM
    [J]. JOURNAL OF AFFECTIVE DISORDERS, 1992, 26 (01) : 31 - 43
  • [3] BAXTER LR, 1989, ARCH GEN PSYCHIAT, V46, P243
  • [4] BECK CHM, 1995, J PSYCHIATR NEUROSCI, V20, P25
  • [5] Bonne O, 1996, J NUCL MED, V37, P1075
  • [6] Pathophysiological significance of cerebral perfusion abnormalities in major depression-trait or state marker?
    Bonne, O
    Krausz, Y
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 1997, 7 (03) : 225 - 233
  • [7] Regional brain metabolic changes in patients with major depression treated with either paroxetine or interpersonal therapy -: Preliminary findings
    Brody, AL
    Saxena, S
    Stoessel, P
    Gillies, LA
    Fairbanks, LA
    Alborzian, S
    Phelps, ME
    Huang, SC
    Wu, HM
    Ho, ML
    Ho, MK
    Au, SC
    Maidment, K
    Baxter, LR
    [J]. ARCHIVES OF GENERAL PSYCHIATRY, 2001, 58 (07) : 631 - 640
  • [8] Brain metabolic changes in major depressive disorder from pre- to post-treatment with paroxetine
    Brody, AL
    Saxena, S
    Silverman, DHS
    Alborzian, S
    Fairbanks, LA
    Phelps, ME
    Huang, SC
    Wu, HM
    Maidment, K
    Baxter, LR
    [J]. PSYCHIATRY RESEARCH-NEUROIMAGING, 1999, 91 (03) : 127 - 139
  • [9] Cook I A, 2001, Semin Clin Neuropsychiatry, V6, P113, DOI 10.1053/scnp.2001.21844
  • [10] Altered cerebral energy utilization in late life depression
    Cook, IA
    Leuchter, AF
    Uijtdehaage, SHJ
    Osato, S
    Holschneider, DH
    Abrams, M
    Rosenberg-Thompson, S
    [J]. JOURNAL OF AFFECTIVE DISORDERS, 1998, 49 (02) : 89 - 99